Determining optimum hemoglobin sampling for anemia management from every-treatment data

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 11, 2010, Pages 1939-1945

  Gaweda, Adam E ^a   Nathanson, Brian H ^b   Jacobs, Alfred A ^a   Aronoff, George R ^a   Germain, Michael J ^c   Brier, Michael E ^a,d  

^a University of Louisville School of Medicine   (United States)

^b OptiStatim LLC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ACCURACY; ADULT; AGED; ANEMIA; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIALYSIS; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; MALE; MEASUREMENT ERROR; OXYGEN SATURATION; PATIENT MONITORING; PROSPECTIVE STUDY; RELIABILITY; SAMPLING; TREATMENT RESPONSE; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANEMIA; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG MONITORING; FEMALE; FOURIER ANALYSIS; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149309504     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03540410     Document Type: Article

References (24)

1. Berns JS, Fishbane S: CHOIR, CREATE, and anemia treatment in patients with CKD. Semin Dial 20: 277-279, 2007
2. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
3. Locatelli F, Del Vecchio L, Pozzoni P: Anemia and cardiovascular risk: The lesson of the CREATE Trial. J Am Soc Nephrol 17: S262-S266, 2006
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
5. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
6. Yee J, Zasuwa G, Frinak S, Besarab A: Hemoglobin variability and hyporesponsiveness: Much ado about something or nothing? Adv Chronic Kidney Dis 16: 83-93, 2009
7. Shimazaki M: Difference in hemoglobin concentration by timing of blood sampling in hemodialysis patients. Dialysis Transplant 38: 350-353, 2009
8. Brooks D: Frequent assessment of longitudinal laboratory trends: A key to minimizing hemoglobin variability in patients on dialysis. Nephrol Nurs J 34: 435-439, 2007
9. Geller AB, DeVita MV, Marku-Podvorica J, Rosenstock JL, Panagopoulos G, Michelis, MF: Increase in post-dialysis hemoglobin can be out of proportion and unrelated to ultrafiltration. Dialysis Transplant 39: 57-62, 2010
10. Movilli E, Pertica N, Camerini C, Cancarini GC, Brunori G, Scolari F, Maiorca R: Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 39: 850-853, 2002
11. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S11-S145, 2006
12. EPOGEN/PROCRIT Label Information. U.S. Food and Drug Administration, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 103234s5199lbl.pdf. Accessed April 2, 2010
13. Khan I, Krishnan M: Frequency of Hb monitoring in dialysis units is associated with facility-level Hb variability. 2007 Spring Clinical Meeting of the National Kidney Foundation. Orlando, FL, April 10-14, 2007
14. Will EJ, Richardson D, Tolman C, Bartlett C: Development and exploitation of a clinical decision support system for the management of renal anaemia. Nephrol Dial Transplant 22[Suppl 4]: iv31-iv36, 2007
15. Ho WR, Germain MJ, Garb J, Picard S, Mackie M-K, Bartlett C, Will EJ: Use of 12x/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability. Nephrol Dial Transplant 25: 2710-2714, 2010
16. Crit-Line III TQA User Manual, Kaysville, UT, Hema Metrics, 2006
17. Bruce EN: Biomedical Signal Processing and Signal Modeling, New York, Wiley, 2001
18. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1: 1205-1210, 2006
19. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, Feldman HI: History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 3: 777-782, 2008
20. Fishbane S, Berns JS: Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 22: 2129-2132, 2007 (Pubitemid 47244687)
21. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3: 133-138, 2008
22. Ehrmeyer SS, Laessig RH, Leinweber JE, Oryall JJ: 1990 Medicare/CLIA final rules for proficiency testing: minimum intralaboratory performance characteristics (CV and bias) needed to pass. Clin Chem 36: 1736-1740, 1990
23. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18: 3164-3170, 2007
24. Boudville NC, Djurdjev O, Macdougall IC, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Urena P, Inigo P, Minutolo R, Haviv YS, Yeates K, Aguera ML, MacRae JM, Levin A: Hemoglobin variability in nondialysis chronic kidney disease: Examining the association with mortality. Clin J Am Soc Nephrol 4: 1176-1182, 2009